A family of plasma enzymes named amine oxidases contribute to a lack of survival of hematopoietic progenitor cells in vitro by oxidizing the amines released into the medium into cytotoxic and mutagenic hydrogen peroxide and aldehydes. This short-term toxicity manifests as low cloning efficiencies. Inhibitors of plasma amine oxidases prevent these toxic effects and increase cloning efficiencies for murine CFU-E CFU-Erythroid and CFU-Granulocyte/macrophage. These inhibitors can substitute for 2- mercaptoethanol in theCFU-E assay, providing an explanation for the stimulatory effects of thiols originally discovered by Iscove. However, these enzyme inhibitors are toxic to human cells, so other approaches are needed to eliminate amine oxidase toxicity. Serum-free media do not necessarily circumvent this problem, because many 'purified' proteins oradditives required for these media contain amine oxidases as contaminants. These enzymes also cause long-term toxicity, such as the crisis of spontaneous transformation in cultures of mouse embryo cells. These data suggest that amine oxidase toxicity is ubiquitous in vitro, and, furthermore, that the development of culture supplements devoid of amine oxidases may facilitate advances in the study and manipulation of stem cells ex vivo. In Phase I, we propose to determine which plasma amine oxidases cause toxicity. In Phase II, wewill develop technology to eliminate deleterious amine oxidases from the culture supplements, confirm that their elimination prevents short- and long-term toxicities, and apply this new cell culture technology toward the development of stem cell lines fromnormal and malignant human bone marrow, breast, prostate, and lymph node, including lymphomas.Such cell lines may prove valuable for carcinogenesis and mutagenesis studies, for in vitro assays for identifying new anti-cancer drugs, and for stabilizing the genome of hybridomas (currently cultured in 2-mercaptoethanol). The technology holds promise for a base from which many of the in vitro goals of """"""""Healthy People-2000"""""""" may be achieved.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Small Business Innovation Research Grants (SBIR) - Phase I (R43)
Project #
1R43CA057118-01
Application #
3493154
Study Section
Hematology Subcommittee 2 (HEM)
Project Start
1992-07-01
Project End
1992-12-31
Budget Start
1992-07-01
Budget End
1992-12-31
Support Year
1
Fiscal Year
1992
Total Cost
Indirect Cost
Name
Cancer Prevention Institute
Department
Type
DUNS #
City
Dayton
State
OH
Country
United States
Zip Code
45439